English
Français
Why medical device innovation needs a connected lifecycle foundation
Stockholm City Hall, now one of the city’s most famous landmarks, started as a bold idea along the waterways that earned Stockholm the nickname “Venice of the North.” The building was designed in 1903 and opened in 1923, but it was not built from a single plan. Over twenty years, it evolved through refinement, debate, craftsmanship, and ongoing adjustments. It was more than bricks or towers; it was about bringing many elements together to create something inspiring and lasting.
This story is similar to what medical device companies face today. Breakthrough ideas are important, but making a real impact means bringing together different disciplines, requirements, decisions, and stakeholders into a unified effort.
For me, one of the main lessons from The MedTech Forum 2026 in Stockholm was that many of the industry’s biggest challenges are not just technical, they are about managing the entire product lifecycle.
There is no shortage of innovation in the medical device industry. AI-powered devices, digital health tools, connected diagnostics, real-world data, robotics, and new care models are all advancing fast. Still, turning these ideas into approved, adopted, and improved products is a complex process.
Innovation does not follow a simple path. It goes through steps like gathering evidence, meeting regulatory requirements, ensuring quality, managing product data, collecting clinical feedback, handling supply chain issues, learning from post-market data, and gaining market access.
Health data as strategic infrastructure
A recurring theme throughout the forum was the growing role of health data as a strategic asset. Data is no longer simply a byproduct of product use, clinical workflows, or patient care. Increasingly, it is becoming part of the evidence base that shapes regulatory decisions, health technology assessment, reimbursement, product improvement, and patient outcomes.
Large-scale initiatives like federated health data platforms are designed to unlock the value of health data across Europe while maintaining trust, interoperability, privacy, and compliance. Better use of heterogeneous data, stronger evidence generation, more informed regulatory and HTA decision-making, and ultimately more patient-centered healthcare systems show great promise.
But the challenge is equally clear. Data only becomes useful when it can be trusted, connected, governed, and interpreted in context.
For medical device companies, the question is no longer whether they need a digital thread; it is whether they can afford not to have one. It is whether that digital thread is connected enough to support regulated decisions across product development, quality, risk, regulatory, manufacturing, and post-market performance.
Regulation is shifting from crisis response to system performance
Regulatory complexity was another major topic at the forum. Following the European Commission’s December 2025 proposal to simplify aspects of the Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR), the conversation is shifting from short-term capacity relief to a bigger question.
How can Europe build a regulatory system that is predictable, sustainable, innovation-friendly, and still rigorous in terms of patient safety and performance?
A strong regulatory system is not only about compliance at a single point in time. It is about how efficiently and confidently companies can generate evidence, manage change, maintain traceability, engage with notified bodies, respond to new requirements, and keep products safe and effective throughout their lifecycle.
The companies best positioned for the future will be those that can connect requirements, design controls, risk management, quality events, technical documentation, clinical evidence, and post-market performance in a way that is transparent, adaptable, and audit-ready.
Agentic AI needs a connected foundation
AI was present throughout the forum conversations, but one of the most interesting discussions focused on agentic AI in post-market processes. This reflects a broader shift in the industry: AI is moving beyond experimentation and into operational workflows.
In post-market review, an AI agent could help compare trends in complaints, service records, design history, risk files, and field performance data. But that only works if those sources are connected, trusted, and traceable. Otherwise, AI simply moves faster through fragmented information.
AI is only as strong as its foundation. For agentic AI to be useful in regulated environments, it needs access to trusted, governed, traceable, and contextualized data. It also needs validation, monitoring, documentation, and oversight that align with evolving regulatory expectations, including the EU AI Act.
That means medical device companies should not think about AI as a layer that can simply be added on top of fragmented processes. The real opportunity is to combine intelligent agents with a governed product intelligence, enabling AI to support decisions across engineering, quality, regulatory, clinical, manufacturing, and market domains.
From complexity to clarity
The message from MedTech Forum 2026 was clear: the industry has enormous momentum, but innovation alone will not be enough. The next phase of progress will depend on how well companies connect innovation to evidence, compliance, quality, market access, and patient outcomes.
This is one of the central tensions in industry today. Innovation is accelerating, but the route to patient access can remain slow and fragmented. Companies are being asked to innovate faster, prove compliance more efficiently, respond to regulatory changes, manage growing product complexity, demonstrate value, and learn continuously from post-market performance. Doing that with disconnected systems and fragmented data is increasingly difficult.
When evidence, product data, risk, quality, clinical feedback, and regulatory strategy are connected from the beginning, companies are better equipped to support decision-making across the full journey from concept to patient impact.
That foundation changes how companies operate. When lifecycle data is connected, teams can move with more confidence across design decisions, regulatory updates, quality signals, clinical evidence, and post-market performance. The result is not just better data management. It is a clearer path from product innovation to patient impact.
Medical device companies can do what Stockholm City Hall represents so well: bring many moving parts together into something coherent, durable, and built for lasting impact. By turning lifecycle complexity into clarity, companies can create the connected, compliant, AI-ready foundation needed for faster, safer, and more sustainable innovation.
Aras’ medical device solutions help companies connect data, processes, and decisions across the full product lifecycle to improve traceability, reduce manual effort, strengthen compliance, and create the digital thread needed for more intelligent, adaptive ways of working. Read Powering Medical Device Success with a Digital Thread-Driven PLM Strategy to discover how the right PLM platform can provide a competitive advantage.
